**Traders should treat Morgan Stanley's upgrade as a high-conviction bullish call given the massive PT hike, but the heavy insider selling and mixed institutional flows create a cautionary backdrop. The stock already trades above consensus targets, so upside may be limited unless earnings or pipeline catalysts emerge.**
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 20 $148.99entry
- T+1 · 3mo ago +2.39%α +1.98% · $152.55
- T+5 · 3mo ago +0.37%α −0.75% · $149.54
- T+20 · 2mo ago −1.42%α −1.42% · $146.87
- T+60 · 4d ago −0.83%α +0.25% · $147.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Morgan Stanley upgraded Merck & Co., Inc. (MRK) from Equal-Weight to Overweight on August 20, 2026, with a new price target of $179, a massive 54.3% increase from its prior $116 target. The upgrade is part of a two-firm cluster on MRK, with RBC Capital simultaneously downgrading to Sector Perform (PT $150). Morgan Stanley's call is contrarian to the consensus mean target of $137.73 and median of $142, but aligns with the bullish tilt in consensus (69% Buy/Strong Buy). The firm's 55% accuracy on 4,986 calls is below average among covering firms, and its 43% accuracy on 7 MRK calls is also below average. The stock trades at $152.20, already above the consensus mean and median, implying 17.6% upside to Morgan Stanley's new target. Momentum is mixed: 2 upgrades and 1 downgrade in 30 days, with EPS revisions slightly negative for the current quarter (1 up, 5 down in 30 days). Insider selling is heavy, with five sales totaling ~$14.3M in August, including a $10.7M sale by EVP Zachary Jennifer, which diverges from the bullish analyst signal. The bottom line: Morgan Stanley's bold PT hike is a standout, but the firm's below-average track record on MRK and heavy insider selling warrant caution.
Impact Score
Consensus & Targets
Consensus is 69% Buy/Strong Buy (9 strong buy, 16 buy), 31% Hold (11 hold), 0% Sell. This is a strongly bullish consensus, with 25 of 36 analysts recommending buying. Morgan Stanley's upgrade aligns with the majority view but is more aggressive on price target.
Current price: $152.20. Consensus mean target: $137.73 (implied downside of -9.5%). Median: $142 (downside -6.7%). High: $155 (upside +1.8%). Low: $105 (downside -31%). Morgan Stanley's new PT of $179 is the highest among all covering analysts, implying 17.6% upside and sitting well above the consensus mean and median.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-20 | RBC Capital | downgrade | Sector Perform | $150.00 |
| 2026-08-20 | Morgan Stanley | upgrade | Overweight | $179.00 |
| 2026-08-12 | Daiwa Capital | upgrade | Outperform | $143.00 |
| 2026-08-11 | Argus Research | maintain | Buy | $145.00 |
| 2026-08-05 | Guggenheim | maintain | Buy | $146.00 |
| 2026-07-29 | Barclays | maintain | Overweight | $150.00 |
| 2026-07-13 | JP Morgan | maintain | Overweight | $140.00 |
| 2026-07-13 | BMO Capital | maintain | Outperform | $142.00 |
| 2026-07-13 | Guggenheim | maintain | Buy | $145.00 |
| 2026-07-09 | Morgan Stanley | maintain | Equal-Weight | $113.00 |
30-day analyst activity: 2 upgrades (Morgan Stanley, Daiwa Capital) and 1 downgrade (RBC Capital). EPS revisions: current quarter (0q) has 1 up and 5 down in 30 days, with EPS declining from $2.30 to $2.21. Next quarter (+1q) has 2 up and 4 down. Full-year (+1y) has 5 up and 4 down. Overall, estimates are being revised slightly lower for near-term quarters but stable for the full year.
Firm Track Record: Morgan Stanley
Morgan Stanley accuracy: 55% on 4986 calls | avg return: 4.3%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 12 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Deutsche Bank | 100% | 2/2 | 9.7% | top tier |
| BMO Capital | 50% | 2/4 | 0.7% | below average |
| Morgan Stanley | 43% | 3/7 | 2.8% | below average |
| Wells Fargo | 40% | 2/5 | 3.8% | below average |
| B of A Securities | 33% | 1/3 | -0.2% | below average |
| Guggenheim | 25% | 1/4 | -7.8% | below average |
| Truist Securities | 20% | 1/5 | -10.3% | below average |
| Cantor Fitzgerald | 9% | 1/11 | -5.5% | below average |
| Barclays | 0% | 0/2 | -7.6% | below average |
| Berenberg | 0% | 0/2 | 11.6% | below average |
Morgan Stanley has a 55% accuracy rate on 4,986 calls overall, with an average return of 4.3%. On MRK specifically, they are 3 for 7 (43% accuracy), below average. Among covering firms, Deutsche Bank leads with 100% accuracy on 2 calls (avg return 9.7%), while Cantor Fitzgerald is worst at 9% on 11 calls (avg return -5.5%). Morgan Stanley's call is contrarian to its own below-average track record on MRK.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $2.75 | $2.62 to $2.87 | $67.1B | ↑13 ↓0 |
| 0q | $2.21 | $2.01 to $2.41 | $17.3B | ↑2 ↓0 |
| +1y | $9.56 | $8.33 to $10.36 | $70.3B | ↑6 ↓0 |
| +1q | $1.96 | $1.86 to $2.09 | $16.9B | ↑4 ↓0 |
Cross-Platform Signals
Insider trades: Five sales totaling ~$14.3M in August, including a $10.7M sale by EVP Zachary Jennifer on Aug 12 and a $1.46M sale by EVP DeLuca Richard R. on Aug 12. No insider buys. This is a strong bearish divergence from the bullish analyst signal. Institutional changes are mixed: Zurich Cantonalbank added 44.7% ($190M), while First Trust Advisors trimmed 42% ($333M). Short interest ratio is 56.8%, indicating elevated bearish positioning. No congressional trades reported.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 Now $144.46 −2.23% settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Entry $148.05 Now $144.46 −2.42% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $144.46 +0.15% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $144.46 −1.28% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $144.46 −0.56% settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $144.46 −1.89% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers